Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023-Reference-Cited by-同舟云学术

Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023

Published:2024-01-18 Issue:3 Volume:29 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Antunes Liliana¹^ORCID,Mazagatos Clara²³^ORCID,Martínez-Baz Iván⁴⁵^ORCID,Gomez Verónica⁶^ORCID,Borg Maria-Louise⁷,Petrović Goranka⁸^ORCID,Duffy Róisín⁹,Dufrasne François E¹⁰^ORCID,Dürrwald Ralf¹¹,Lazar Mihaela¹²^ORCID,Jancoriene Ligita¹³^ORCID,Oroszi Beatrix¹⁴^ORCID,Husa Petr¹⁵^ORCID,Howard Jennifer¹^ORCID,Melo Aryse¹⁶^ORCID,Pozo Francisco¹⁷^ORCID,Pérez-Gimeno Gloria²³^ORCID,Castilla Jesús⁴⁵^ORCID,Machado Ausenda⁶^ORCID,Džiugytė Aušra⁷^ORCID,Karabuva Svjetlana¹⁸,Fitzgerald Margaret⁹^ORCID,Fierens Sébastien¹⁹,Tolksdorf Kristin²⁰,Popovici Silvia-Odette²¹^ORCID,Mickienė Auksė²²,Túri Gergő¹⁴^ORCID,Součková Lenka¹⁵^ORCID,Nicolay Nathalie²³^ORCID,Rose Angela MC¹^ORCID,

Affiliation:

1. Epiconcept, Paris, France

2. Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain

3. National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain

4. CIBER Epidemiología y Salud Pública, Madrid, Spain

5. Instituto de Salud Pública de Navarra – IdiSNA, Pamplona, Spain

6. Epidemiology Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal

7. Infectious Disease Prevention and Control Unit (IDCU), Health Promotion and Disease Prevention, Msida, Malta

8. Croatian Institute of Public Health, Zagreb, Croatia

9. Health Service Executive-Health Protection Surveillance Centre (HPSC), Dublin, Ireland

10. National Influenza Centre Laboratory of Viral Diseases, Sciensano, Brussels, Belgium

11. National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany

12. Cantacuzino National Military-Medical Institute for Research and Development, Bucharest, Romania

13. Clinic of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Medical Faculty, Vilnius University, Lithuania

14. National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary

15. University Hospital Brno, Masaryk University, Brno, Czechia

16. Infectious Diseases Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal

17. National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain

18. University Hospital Centre Split, Split, Croatia

19. Service Epidemiology of Infectious Diseases, Sciensano, Brussels, Belgium

20. Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany

21. National Institute of Public Health, National Centre for Communicable Diseases Surveillance and Control, Bucharest, Romania

22. Department of Infectious Diseases, Lithuanian University of Health Sciences, Kaunas, Lithuania

23. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

Abstract

We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14–89 days post-vaccination, 15% (95% CI: −12 to 35) at 90–179 days, and lower to no effect thereafter.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference12 articles.

1. European Medicines Agency (EMA). Authorised COVID-19 vaccines. Amsterdam: EMA. [Accessed: 2 Nov 2023]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines

2. European Centre for Disease Prevention and Control (ECDC). Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU/EEA. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Overview-vaccination-strategies-COVID-19-8-September-2022.pdf

3. European Centre for Disease Prevention and Control (ECDC). ECDC de-escalates BA.2, BA.4 and BA.5 from its list of variants of concern. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/en/news-events/ecdc-de-escalates-ba2-ba4-and-ba5-its-list-variants-concern

4. European Centre for Disease Prevention and Control (ECDC). Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with severe acute respiratory infection, laboratory-confirmed with SARS-CoV-2 or with seasonal influenza - Version 2.0. Stockholm: ECDC. 2023. Available from: https://www.ecdc.europa.eu/en/publications-data/core-protocol-ecdc-studies-covid-19-vaccine-effectiveness-against-0

5. Peralta-Santos A. Assessment of COVID-19 surveillance case definitions and data reporting in the European Union. Briefing requested by the ENVI committee. Brussels: European Parliament; 2020. Available from: http://www.europarl.europa.eu/RegData/etudes/BRIE/2020/652725/IPOL_BRI(2020)652725_EN.pdf